期刊文献+

马兜铃酸Ⅰ致癌作用及其与代谢酶关系的研究进展 被引量:6

Progress in Aristolochic Acid Carcinogenesis and Its Related Metabolic Enzymes
下载PDF
导出
摘要 马兜铃酸(aristolochic acid,AA)广泛存在于马兜铃科马兜铃属中草药中,是马兜铃酸肾病(aristolochic acid nephropathy,AAN)的致病因素,此类肾病患者可伴发泌尿系统肿瘤,阐明马兜铃酸的致癌机制成为其毒性研究的一大焦点。马兜铃酸Ⅰ(AAⅠ)是马兜铃酸的主要毒性成分,其在体内经氧化还原后活化,与DNA共价结合形成加合物而诱发癌变。本文综述参与AAⅠ氧化还原的代谢酶及其代谢过程在AAⅠ致癌中的作用。 Aristolochic acid(AA),a major active component of Aristolochiaceae Aristolochia herbs,is the pathogenic factor of aristolochic acid nephropathy(AAN). And AAN patients were usually complicated by urinary cancer.Therefore,the study on the carcinogenesis mechanisms of AA has become the focus in its toxicity research. Recently,researches have demonstrated that aristolochic acidⅠ(AAⅠ)was the main toxic component of AA,and was activated following the oxidation-reduction process. After activation, AA Ⅰ can induce carcinoma through forming AA Ⅰ-DNA adducts. This review summarizes the latest research of the enzymes participating in AAⅠ metabolism and their roles in the progress of AA carcinogenesis,which may provide references for follow-up research and its clinical application.
出处 《中药新药与临床药理》 CAS CSCD 北大核心 2014年第6期765-769,共5页 Traditional Chinese Drug Research and Clinical Pharmacology
基金 江苏省科技厅自然科学基金面上项目(BK2012852) 江苏省高校优势学科建设工程资助项目(2011XYZ4-003) 国家自然科学青年基金(30701106)
关键词 马兜铃酸 马兜铃酸Ⅰ 马兜铃酸Ⅰ-DNA加合物 代谢酶 致癌 Aristolochic acid Aristolochic acid Ⅰ Aristolochic acid Ⅰ-DNA adduct Metabolic enzyme Carcinogenesis
  • 相关文献

参考文献33

  • 1曾又佳,阳晓,余学清.马兜铃酸肾病研究进展[J].中华肾脏病杂志,2010(2):144-146. 被引量:8
  • 2Jonge H, Vanrenterghem Y. Aristolochic acid: the common culprit of Chinese herbs nephropathy and Balkan endemic nephropathy[J]. Nephrol Dial Transplant, 2008, 23(1): 39-41.
  • 3Grollman AP, Shihutani S, Moriya M, et al. Aristolochic acid and the eiology of endemic(Balkan) nephropathy[J]. Proc Nail Acad Sci USA, 2007, 104(29): 12129-12134.
  • 4Arh VM, Ferluga D, Stiborova M, et al. Is aristolochic acid a risk factor for Balkan endemic nephropathy-associated urothelial cancer? [J]. IntJCancer, 2002, 101(5): 500-502.
  • 5Shibutani S, Dong H, Suzuki N, et al. Selective toxicity of aris toloehic acids I and II [J]. Drug MetabDispos, 2007, 35(7): 1217- 1222.
  • 6Lemy A, Wissing KM, Nortier J, et al. Late on set of bladder urothelial carcinoma after kidney transplantation for end-stage aristolochic acid nephropathy: a ease series with 15-year follow-up[J]. Am J Kidney Dis, 2008, 51(3) , 471-477.
  • 7Martinez MC, Nortier J, Vanherweghem JL, et al. Progression rate of Chinese herb nephropathy: impact of Aristolochiafangchi ingested dose [J]. Nephrol Dial Transplant, 2002, 17( 11 ) : 408-412.
  • 8陈敏,宫丽崑,任进.代谢酶在马兜铃酸肾病中的作用[J].中草药,2012,43(2):388-392. 被引量:6
  • 9ChanW, Luo HB, Cai Z, et al. Investigation of the metabolism and reductive activation of carcinogenic aristolochic acid in rats [J]. Drug Metab Dispos, 2007, 35(6), 866-874.
  • 10Shibutani S, Bonala RR, Grollman AP, et al. Detoxification of aristolochic acid I by O-demethylation: less nephrotoxicity and genotoxicity of aristolochic acid Ia in rodents [J]. Int J Cancer, 2010, 127(5): 1021-1027.

二级参考文献13

共引文献17

同被引文献76

引证文献6

二级引证文献69

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部